<DOC>
	<DOCNO>NCT02638116</DOCNO>
	<brief_summary>The purpose study evaluate Effect Omeprazole Pharmacokinetics Ibrutinib Healthy Adults .</brief_summary>
	<brief_title>A Drug Interaction Study Assess Effect Omeprazole Pharmacokinetics Ibrutinib Healthy Adults</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , sequential-design drug interaction study assess effect omeprazole pharmacokinetics ibrutinib metabolite PCI-45227 healthy participant . The study mainly consist 3 Phases : Screening Phase ( within 21 day prior first dose study medication ) , treatment Phase , follow Phase ( 10 12 day last dose study medication ) . In treatment Phase , participant receive Ibrutinib 560 milligram ( mg ) orally ( 4 x 140 mg capsule ) Day 1 Day 7. participant receive Omeprazole dose 40 mg tablet orally Days 3 7 . The total duration study participant approximately 29 32 day . Blood sample collect evaluation pharmacokinetics Ibrutinib . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate study If woman , must childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) &gt; 40 International unit [ IU ] / Liter [ L ] ) ; surgically sterile If woman , must negative serum Î²human chorionic gonadotropin ( hCG ) pregnancy test Screening negative urine pregnancy test Day1 Willing adhere prohibition restriction specify protocol If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency ( creatinine clearance 60 milliliter [ mL ] / minute [ min ] ) , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , coagulation , clinical chemistry , Screening deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) Screening deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol hormonal replacement therapy within 14 day first dose study drug schedule completion study History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 5th edition ) ( DSMIV ) criterion within 2 year Screening positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , benzodiazepine ) Screening Day1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ibrutinib</keyword>
	<keyword>Proton pump inhibitor</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug Interaction</keyword>
</DOC>